Medullary sponge kidney (MSK)
Also known as: Medullary sponge kidney, Kidney, Renal, Nephric, Nephron
Methodology & AI Transparency ⓘ
Medullary sponge kidney (MSK) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Medullary sponge kidney (MSK) (also termed Medullary sponge kidney or Kidney)—coded clinically as Q61.5 across Kidney & Renal guidelines—combines NSAID/nephrotoxin avoidance [Medullary sponge kidney (MSK) Q61.5] with structured follow-up of Urine Albumin-to-Creatinine Ratio in Medullary sponge kidney (MSK) (Q61.5: (uACR)) (< 15 mg/g (< 30 mg/g normal) (Q61.5)).
- 2 Real-world patient consensus: Clinical coding for Medullary sponge kidney (MSK) uses ICD-10 Q61.5 across Kidney & Renal specialty care.
- 3 Typical cash cost range: Workup highlights for Medullary sponge kidney (MSK) (Q61.5): NSAID/nephrotoxin avoidance [Medullary sponge kidney (MSK) Q61.5].
- 4 Top reported side effects / signs: Objective lab/clinical target for Medullary sponge kidney (MSK): eGFR (Creatinine + in Medullary sponge kidney (MSK) (Q61.5: Cystatin C)) (>= 90 mL/min/1.73m2 (Q61.5)) and Urine Albumin-to-Creatinine Ratio in Medullary sponge kidney (MSK) (Q61.5: (uACR)).
Ask our AI Specialists anything about Medullary sponge kidney (MSK)
What Is Medullary sponge kidney (MSK)?
Medullary sponge kidney (MSK) (also termed Medullary sponge kidney or Kidney)—coded clinically as Q61.5 across Kidney & Renal guidelines—combines NSAID/nephrotoxin avoidance [Medullary sponge kidney (MSK) Q61.5] with structured follow-up of Urine Albumin-to-Creatinine Ratio in Medullary sponge kidney (MSK) (Q61.5: (uACR)) (< 15 mg/g (< 30 mg/g normal) (Q61.5)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in kidney & renal, Medullary sponge kidney (MSK) (Q61.5) involves erythropoietin decline [Medullary sponge kidney (MSK) Q61.5]. progression correlates with shifts in eGFR (Creatinine + in Medullary sponge kidney (MSK) (Q61.5: Cystatin C)) (>= 90 mL/min/1.73m2 (Q61.5)).
Common Symptoms & Clinical Signs
- • Presentation of Medullary sponge kidney (MSK) (Q61.5): changes in urine in Medullary sponge kidney (MSK) (Q61.5: output volume, nocturnal)
- • Secondary Medullary sponge kidney (MSK) clinical sign: asymptomatic decline in in Medullary sponge kidney (MSK) (Q61.5: eGFR or persistent)
- • Symptom flares in Medullary sponge kidney (MSK) correlating with eGFR (Creatinine + in Medullary sponge kidney (MSK) (Q61.5: Cystatin C)) deviation outside >= 90 mL/min/1.73m2 (Q61.5)
- • Functional kidney & renal impact requiring NSAID/nephrotoxin avoidance [Medullary sponge kidney (MSK) Q61.5] evaluation (Q61.5)
Medullary sponge kidney (MSK) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q61.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Medullary sponge kidney (MSK) (Q61.5: Cystatin C)) | >= 90 mL/min/1.73m2 (Q61.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Medullary sponge kidney (MSK) (Q61.5: (uACR)) | < 15 mg/g (< 30 mg/g normal) (Q61.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Medullary sponge kidney (MSK) (Q61.5: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (Q61.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Medullary sponge kidney (MSK)
Treatment selection for Medullary sponge kidney (MSK) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Medullary sponge kidney (MSK))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of finerenone in patients with chronic kidney disease and This analysis showed that the real-world benefits and safety of finerenone in patients with CKD and T2D was not modified by baseline diuretic use. European journal of heart failure • 2025-05-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39823276 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III gold-standard blind, compared against a dummy pill (placebo), These findings suggest that SPP-004 is safe and may provide therapeutic effect for LS patients who achieved an initial clinical response. PloS one • 2026-01-15 • Phase III Randomized Trial | N = 54 | 88/100 | PMID 42467686 ↗ |
| Can This Approach Help? Inside the Latest Research on Losartan and amlodipine in renally impaired hypertensive The treatment difference was statistically significant (P = 0.021). Kidney international. Supplement • 1998-12-15 • Randomized Controlled Trial | N = 48 | 88/100 | PMID 9839295 ↗ |
| New Insights on Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5:: What a 290-Participant Study Found This analysis generated evidence supportive of the psychometric properties of the GP5 as a fit-for-purpose measure to assess treatment tolerability in patients. Journal of patient-reported outcomes • 2024-12-19 • Phase III Randomized Trial | N = 290 | 87/100 | PMID 39694978 ↗ |
| New Insights on Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance: What a 223-Participant Study Found Switching stable kidney transplant recipients from CNI-based to belatacept-based immunosuppression was associated with a similar rate of death or graft loss, improved kidney function, and a numerically higher BPAR rate but a... Journal of the American Society of Nephrology : JASN • 2021-12-01 • Phase III Randomized Trial | N = 223 | 82/100 | PMID 34706967 ↗ |
Medullary sponge kidney (MSK) Patient Community & “People Like Me” Threads
Filter Medullary sponge kidney (MSK) community threads and patient logs by age, biological sex, dosage, and treatment duration.